SCHEMBL23987183

SCHEMBL23987183

Cc1nc2ccc(/C=C3\NC(=S)NC3=O)cc2s1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CLK1 P49759 6/20 0.62
▸ DYRK1A Q13627 6/20 0.62
▸ DYRK1B Q9Y463 6/20 0.62
▸ DYRK2 Q92630 4/20 0.62
▸ CSNK2A2 P19784 1/20 0.62
▸ CSNK2B P67870 1/20 0.62
▸ CSNK2A1 P68400 1/20 0.62
▸ CLK4 Q9HAZ1 5/20 0.61
▸ DYRK3 O43781 3/20 0.61
▸ CLK2 P49760 3/20 0.61
▸ CLK3 P49761 1/20 0.61
▸ MEN1 O00255 4/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ MAPT P10636 3/20 0.50
▸ IDH1 O75874 3/20 0.46
▸ CBS P35520 1/20 0.45
▸ CTSB P07858 1/20 0.44
▸ ELANE P08246 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30145000 1.00 CLK1 (0.62) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL30145013 0.77 CLK1 (1.00) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL25590187 0.77 CLK1 (0.52) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL23499923 0.77 CLK1 (1.00) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL28945469 0.77 CLK1 (0.54) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL30275506 0.76 CLK1 (0.51) CLK1DYRK1ADYRK1BDYRK2CLK4
SCHEMBL24904264 0.73 CSNK2A2 (0.64) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL30363450 0.73 CSNK2A2 (0.64) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL26094685 0.73 MEN1 (0.60) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL26092772 0.73 MEN1 (0.73) CLK1DYRK1ADYRK1BDYRK2CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-06-01 — — US disclosed
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-06-01 — — US disclosed
CN-115515953-A Novel imidazolidinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 珀哈制药公司 2022-12-23 — — CN disclosed
WO-2021219828-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2021-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 CLK1, CLK2, CLK3 CLK1 1/4885DYRK1A 18/4885DYRK1B 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback